XIGDUO® XR

Drug Information Related Patent

Hold Company

ASTRAZENECA AB

Learn More

Dosage and Administration

TABLET, EXTENDED RELEASE;ORAL

Specification

5MG,500MG; 5MG,1GM; 10MG,500MG; 10MG,1GM; 2.5MG,1GM

Indication

XIGDUO® XR is considered as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Use

Instructions for Use

API

DAPAGLIFLOZIN
METFORMIN HYDROCHLORIDE

API Structure

We Supply

DAPAGLIFLOZIN

Note:

In-house Standard
Facility GMP
USMF/DMF/China DMF/CDE

METFORMIN HYDROCHLORIDE

Note:

CP/BP/EP/JP/USP
Facility GMP
Product GMP
ASMF/USMF/US-FDA/KFDA/WHO/CEP/KDMF

null

Note:

null

Drug Patent

Patent No	Expiration Date
6515117	2025/10/4
7919598	2029/12/16
8501698	2027/6/20
8685934	2030/5/26
9616028	2030/11/12

API Patent

Patent No	Expiration Date
6515117	2025/10/4

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION